Cergentis is a genomics-focused biotechnology company that developed the patented Targeted Locus Amplification (TLA) technology, a widely published Next Generation Sequencing (NGS)-based enrichment strategy. Thanks to its unique resolution and unmatched capabilities, TLA offers unique advantages in the quality control of advanced genetic engineering.

Our TLA-based genetic solutions can be applied to determine:
• All sequence changes resulting from targeted genome editing.
• All vector integration sites.
• Structural changes in the host genome surrounding vector integration sites.
• Single nucleotide variants in a vector sequence.
• Structural changes in a vector sequence.
• Co-integration of backbone or contaminating E.coli sequences

Cergentis has established itself as the go-to partner for the characterization of genetically engineered cell lines, cell and gene therapy products and animal models for the global biopharmaceutical industry and leading research institutes. We develop and sell services and in-house solutions for targeted and complete sequencing of (trans)genes and gene editing events and provide services for the support in R&D in these fields.

Our expertise lies in the analysis of (complex) genetic engineering projects in various organisms and sample types, including CHO, human cell lines (T cells, HEK293, HeLa, etc.) and transgenic animals (mice, rats, goats, pigs, etc.).
TLA data is widely used in the selection and characterization of genetically engineered cell lines and animals and has been widely used in support of >70 peer-reviewed publications.

TLA obsoletes the use of southern blot and FISH, yielding NGS-based data at a fraction of the turnaround time and costs. Moreover, Cergentis studies are performed and reported to be acceptable for regulatory filings in accordance with FDA and EMA requirements (CTD module 3.2.S.2.3.) and have been used in both early (IND) and late stage (BLA) dossiers.

It is our mission to improve the quality of genetic research: supporting biopharmaceutical R&D will accelerate the development of new treatments with better outcomes for patients all over the world.